Hepatic stellate cells: A target for the treatment of liver fibrosis

J. Wu, Mark A Zern

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

Hepatic fibrosis is a wound-healing process that occurs when the liver is injured chronically. Hepatic stellate cells (HSC) are responsible for the excess production of extracellular matrix (ECM) components. The activation of HSC, a key issue in the pathogenesis of hepatic fibrosis, is mediated by various cytokines and reactive oxygen species released from the damaged hepatocytes and activated Kupffer cells. Therefore, inhibition of HSC activation and its relased subsequent events, such as increased production of ECM components and enhanced proliferation, are crucial goals for intervention in the hepatic fibrogenesis cascade. This is especially true when the etiology is unknown or there is no established therapy for the cause of the chronic injury. This review explores the rationale for choosing HSC as a target for the pharmacological, molecular, and other novel therapeutics for hepatic fibrosis. One focus of this review is the inhibition of two cytokines, transforming growth factor-β and platelet-derived growth factor, which are important in hepatic fibrogenesis. A number of new agents, such as Chinese herbal recipes and herbal extracts, silymarin, S-adenosyl-L-methionine, polyenylphosphatidylcholine, and pentoxifylline are also discussed.

Original languageEnglish (US)
Pages (from-to)665-672
Number of pages8
JournalJournal of Gastroenterology
Volume35
Issue number9
DOIs
StatePublished - 2000

Fingerprint

Hepatic Stellate Cells
Liver Cirrhosis
Liver
Fibrosis
Extracellular Matrix
Cytokines
Silymarin
S-Adenosylmethionine
Pentoxifylline
Kupffer Cells
Platelet-Derived Growth Factor
Transforming Growth Factors
Wound Healing
Hepatocytes
Reactive Oxygen Species
Pharmacology
Wounds and Injuries
Therapeutics

Keywords

  • Chinese herbal medicine
  • Cirrhosis
  • Fibrosis
  • Hepatic stellate cells
  • Liver
  • Platelet-derived growth factor
  • Reactive oxygen species
  • S-adenosyl-L-methionine
  • Transforming growth factor-β
  • Treatment
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatic stellate cells : A target for the treatment of liver fibrosis. / Wu, J.; Zern, Mark A.

In: Journal of Gastroenterology, Vol. 35, No. 9, 2000, p. 665-672.

Research output: Contribution to journalArticle

Wu, J. ; Zern, Mark A. / Hepatic stellate cells : A target for the treatment of liver fibrosis. In: Journal of Gastroenterology. 2000 ; Vol. 35, No. 9. pp. 665-672.
@article{948caea8ec764ac383311733b54201d9,
title = "Hepatic stellate cells: A target for the treatment of liver fibrosis",
abstract = "Hepatic fibrosis is a wound-healing process that occurs when the liver is injured chronically. Hepatic stellate cells (HSC) are responsible for the excess production of extracellular matrix (ECM) components. The activation of HSC, a key issue in the pathogenesis of hepatic fibrosis, is mediated by various cytokines and reactive oxygen species released from the damaged hepatocytes and activated Kupffer cells. Therefore, inhibition of HSC activation and its relased subsequent events, such as increased production of ECM components and enhanced proliferation, are crucial goals for intervention in the hepatic fibrogenesis cascade. This is especially true when the etiology is unknown or there is no established therapy for the cause of the chronic injury. This review explores the rationale for choosing HSC as a target for the pharmacological, molecular, and other novel therapeutics for hepatic fibrosis. One focus of this review is the inhibition of two cytokines, transforming growth factor-β and platelet-derived growth factor, which are important in hepatic fibrogenesis. A number of new agents, such as Chinese herbal recipes and herbal extracts, silymarin, S-adenosyl-L-methionine, polyenylphosphatidylcholine, and pentoxifylline are also discussed.",
keywords = "Chinese herbal medicine, Cirrhosis, Fibrosis, Hepatic stellate cells, Liver, Platelet-derived growth factor, Reactive oxygen species, S-adenosyl-L-methionine, Transforming growth factor-β, Treatment, Tumor necrosis factor-α",
author = "J. Wu and Zern, {Mark A}",
year = "2000",
doi = "10.1007/s005350070045",
language = "English (US)",
volume = "35",
pages = "665--672",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "9",

}

TY - JOUR

T1 - Hepatic stellate cells

T2 - A target for the treatment of liver fibrosis

AU - Wu, J.

AU - Zern, Mark A

PY - 2000

Y1 - 2000

N2 - Hepatic fibrosis is a wound-healing process that occurs when the liver is injured chronically. Hepatic stellate cells (HSC) are responsible for the excess production of extracellular matrix (ECM) components. The activation of HSC, a key issue in the pathogenesis of hepatic fibrosis, is mediated by various cytokines and reactive oxygen species released from the damaged hepatocytes and activated Kupffer cells. Therefore, inhibition of HSC activation and its relased subsequent events, such as increased production of ECM components and enhanced proliferation, are crucial goals for intervention in the hepatic fibrogenesis cascade. This is especially true when the etiology is unknown or there is no established therapy for the cause of the chronic injury. This review explores the rationale for choosing HSC as a target for the pharmacological, molecular, and other novel therapeutics for hepatic fibrosis. One focus of this review is the inhibition of two cytokines, transforming growth factor-β and platelet-derived growth factor, which are important in hepatic fibrogenesis. A number of new agents, such as Chinese herbal recipes and herbal extracts, silymarin, S-adenosyl-L-methionine, polyenylphosphatidylcholine, and pentoxifylline are also discussed.

AB - Hepatic fibrosis is a wound-healing process that occurs when the liver is injured chronically. Hepatic stellate cells (HSC) are responsible for the excess production of extracellular matrix (ECM) components. The activation of HSC, a key issue in the pathogenesis of hepatic fibrosis, is mediated by various cytokines and reactive oxygen species released from the damaged hepatocytes and activated Kupffer cells. Therefore, inhibition of HSC activation and its relased subsequent events, such as increased production of ECM components and enhanced proliferation, are crucial goals for intervention in the hepatic fibrogenesis cascade. This is especially true when the etiology is unknown or there is no established therapy for the cause of the chronic injury. This review explores the rationale for choosing HSC as a target for the pharmacological, molecular, and other novel therapeutics for hepatic fibrosis. One focus of this review is the inhibition of two cytokines, transforming growth factor-β and platelet-derived growth factor, which are important in hepatic fibrogenesis. A number of new agents, such as Chinese herbal recipes and herbal extracts, silymarin, S-adenosyl-L-methionine, polyenylphosphatidylcholine, and pentoxifylline are also discussed.

KW - Chinese herbal medicine

KW - Cirrhosis

KW - Fibrosis

KW - Hepatic stellate cells

KW - Liver

KW - Platelet-derived growth factor

KW - Reactive oxygen species

KW - S-adenosyl-L-methionine

KW - Transforming growth factor-β

KW - Treatment

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=0033781716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033781716&partnerID=8YFLogxK

U2 - 10.1007/s005350070045

DO - 10.1007/s005350070045

M3 - Article

C2 - 11023037

AN - SCOPUS:0033781716

VL - 35

SP - 665

EP - 672

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 9

ER -